Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart C Gordon

Showing results (121-130 of 214) with videos related to

Pageof 22
Sort By:
Journal of Clinical Gastroenterology|March 29, 2021
Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006-2016)Mei Lu, Jia Li, Yueren Zhou, et al.
Journal of Hepatology|March 13, 2019
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infectionDavid Wyles, Ola Weiland, Betty Yao, et al.
The New England Journal of Medicine|November 30, 2007
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis CJohn G McHutchison, Geoffrey Dusheiko, Mitchell L Shiffman, et al.
Journal of Hepatology|October 2, 2012
Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United StatesDwayne M Baxa, Ashish D Thekdi, Alicia Golembieski, et al.
Pharmacogenetics and Genomics|September 25, 2013
Predictors of consent to pharmacogenomics testing in the IDEAL studyAlison B Jazwinski, Paul J Clark, Alexander J Thompson, et al.
Journal of Autoimmunity|May 10, 2005
Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosisKentaro Kikuchi, Zhe-Xiong Lian, Yasuhiko Kimura, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 29, 2015
HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeNancy Reau, Michael W Fried, David R Nelson, et al.
MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports|July 24, 2020
Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020Anne C Moorman, Marie A de Perio, Ronald Goldschmidt, et al.
Digestive Diseases and Sciences|May 25, 2016
Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS)Anne C Moorman, Xin Tong, Philip R Spradling, et al.
Infectious Diseases and Therapy|April 8, 2026
Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated AnalysisCurtis Cooper, Shweta A Raina, Lisa Johnson, et al.
Pageof 22

Showing results (121-130 of 214) with videos related to

Sort By:
Pageof 22
Journal of Clinical Gastroenterology|March 29, 2021
Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006-2016)Mei Lu, Jia Li, Yueren Zhou, et al.
Journal of Hepatology|March 13, 2019
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infectionDavid Wyles, Ola Weiland, Betty Yao, et al.
The New England Journal of Medicine|November 30, 2007
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis CJohn G McHutchison, Geoffrey Dusheiko, Mitchell L Shiffman, et al.
Journal of Hepatology|October 2, 2012
Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United StatesDwayne M Baxa, Ashish D Thekdi, Alicia Golembieski, et al.
Pharmacogenetics and Genomics|September 25, 2013
Predictors of consent to pharmacogenomics testing in the IDEAL studyAlison B Jazwinski, Paul J Clark, Alexander J Thompson, et al.
Journal of Autoimmunity|May 10, 2005
Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosisKentaro Kikuchi, Zhe-Xiong Lian, Yasuhiko Kimura, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 29, 2015
HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeNancy Reau, Michael W Fried, David R Nelson, et al.
MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports|July 24, 2020
Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020Anne C Moorman, Marie A de Perio, Ronald Goldschmidt, et al.
Digestive Diseases and Sciences|May 25, 2016
Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS)Anne C Moorman, Xin Tong, Philip R Spradling, et al.
Infectious Diseases and Therapy|April 8, 2026
Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated AnalysisCurtis Cooper, Shweta A Raina, Lisa Johnson, et al.
Pageof 22